Thermo Scientific Watson LIMS offers enhanced functionality for bioanalytical laboratories

Thermo Fisher Scientific Inc., the world leader in serving science, today announced that its Thermo Scientific Watson LIMS (laboratory information management system) offers enhanced functionality for large molecule bioanalysis in pharmaceutical and contract research organization (CRO) laboratories. Watson LIMS™ now integrates the data from both small and large molecule research within a single database by facilitating the workflow and extending instrument integration to large molecule bioanalysis. Watson extends the flexibility of the cutpoint calculations in the immune response module (IRM) and allows samples analyzed with the IRM to be processed through Watson's incurred sample reanalysis (ISR) functionality.    

The company is featuring Watson LIMS within Thermo Scientific booth 1 at the Vancouver Convention Center (Parkview Terrace - Rooms 1, 2 and 3) during ASMS 2012, being held May 20-24.

Historically, most drug development has revolved around small molecule research, requirements for which have been defined at The Crystal City Conference, However, these methods were not always adequate to manage the complexity of large molecule bioanalysis because the research workflow and data analysis is often quite different for large molecules than it is for small molecules. For pharmaceutical companies with a balanced portfolio and scientists involved in both small and large molecule research, the process of transferring data from one side of the laboratory to the other has been largely a manual process, further complicating the workflow and potentially introducing error. Additional functionality in Watson LIMS now closes the gap between small and large molecule research and brings connectivity to the bioanalytical laboratory.

"With the extended functionality of Watson now encompassing large molecule research as well as small, the bioanalytical laboratory has the industry-leading LIMS managing two previously separate parts of the drug development process," said Dave Champagne, vice president and general manager of Informatics at Thermo Fisher. "This allows scientists in the field to combine activities and processes, thereby saving time and precious resources and increasing the speed at which new compounds are introduced to the market. With the ongoing advances in biomarker research, Watson is perfectly aligned to add value to some of the next decade's most important scientific efforts."